{
    "id": 25472,
    "fullName": "CLDN18 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "CLDN18 over exp indicates an over expression of the Cldn18 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 51208,
        "geneSymbol": "CLDN18",
        "terms": [
            "CLDN18",
            "SFTA5",
            "SFTPJ"
        ]
    },
    "variant": "over exp",
    "createDate": "10/10/2016",
    "updateDate": "10/10/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8770,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, addition of Claudiximab (IMAB362) to chemotherapy consisted of epirubicin, oxaliplatin, and capecitabine (EOX) resulted in improved progression-free survival (9.1 vs 6.1 months) compared to EOX alone in patients with advanced gastric and gastroesophageal junction adenocarcinoma over-expressing Cldn18 (J Clin Oncol 34, 2016 (suppl; abstr LBA4001)).",
            "molecularProfile": {
                "id": 26433,
                "profileName": "CLDN18 over exp"
            },
            "therapy": {
                "id": 4258,
                "therapyName": "Claudiximab",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6736,
                    "pubMedId": null,
                    "title": "FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gast",
                    "url": "http://meetinglibrary.asco.org/content/164788-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8771,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, addition of Claudiximab (IMAB362) to chemotherapy consisted of epirubicin, oxaliplatin, and capecitabine (EOX) resulted in improved progression-free survival (9.1 vs 6.1 months) compared to EOX alone in patients with advanced gastric and gastroesophageal junction adenocarcinoma over-expressing Cldn18 (J Clin Oncol 34, 2016 (suppl; abstr LBA4001)).",
            "molecularProfile": {
                "id": 26433,
                "profileName": "CLDN18 over exp"
            },
            "therapy": {
                "id": 4258,
                "therapyName": "Claudiximab",
                "synonyms": null
            },
            "indication": {
                "id": 4944,
                "name": "gastroesophageal junction adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6736,
                    "pubMedId": null,
                    "title": "FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gast",
                    "url": "http://meetinglibrary.asco.org/content/164788-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26433,
            "profileName": "CLDN18 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}